Establishing a living biobank of patient-derived organoids of intraductal papillary mucinous neoplasms of the pancreas

Beato, Francisca; Reverón, Dayana; Dezsi, Kaleena B.; Ortiz, Antonio; Johnson, Joseph; Chen, Dung-Tsa; Ali, Karla N.; Yoder, Sean; Jeong, Daniel; Malafa, Mokenge P.; Hodul, Pamela J.; Jiang, Kun; Centeno, Barbara A.; Abdalah, Mahmoud A.; Balasi, Jodi A.; Tassielli, Alexandra F.; Sarcar, Bhaswati; Teer, Jamie K.; DeNicola, Gina M.; Permuth, Jennifer B.; Fleming, Jason B.

doi:10.1038/s41374-020-00494-1

Cited by 38 publications

(29 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We will also be performing genotyping for ancestry informative markers to validate self-reported ancestry and plan to conduct molecular profiling of tumor tissue. Finally, based on the promise of pre-clinical models in translational efforts, we plan to leverage the pancreatic tissue collected and preserved through this effort for applications such as generation of patient-derived organoids [ 51 ]. Thus, the FPC will become an enduring resource for the biomedical and disparities community.…”

Section: Discussionmentioning

confidence: 99%

The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pancreatic Cancer

Permuth¹,

Dezsi²,

Vyas³

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

Background: Well-annotated, high-quality biorepositories provide a valuable platform to support translational research. However, most biorepositories have poor representation of minority groups, limiting the ability to address health disparities. Methods: We describe the establishment of the Florida Pancreas Collaborative (FPC), the first state-wide prospective cohort study and biorepository designed to address the higher burden of pancreatic cancer (PaCa) in African Americans (AA) compared to Non-Hispanic Whites (NHW) and Hispanic/Latinx (H/L). We provide an overview of stakeholders; study eligibility and design; recruitment strategies; standard operating procedures to collect, process, store, and transfer biospecimens, medical images, and data; our cloud-based data management platform; and progress regarding recruitment and biobanking. Results: The FPC consists of multidisciplinary teams from fifteen Florida medical institutions. From March 2019 through August 2020, 350 patients were assessed for eligibility, 323 met inclusion/exclusion criteria, and 305 (94%) enrolled, including 228 NHW, 30 AA, and 47 H/L, with 94%, 100%, and 94% participation rates, respectively. A high percentage of participants have donated blood (87%), pancreatic tumor tissue (41%), computed tomography scans (76%), and questionnaires (62%). Conclusions: This biorepository addresses a critical gap in PaCa research and has potential to advance translational studies intended to minimize disparities and reduce PaCa-related morbidity and mortality.

show abstract

Section: Discussionmentioning

confidence: 99%

The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pancreatic Cancer

Permuth¹,

Dezsi²,

Vyas³

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…We will also be performing genotyping for ancestry informative markers using DNA from blood collected via this study to validate self-reported ancestry. Finally, based on the promise of pre-clinical models in translational efforts 79-83 , we also plan to leverage the pancreatic tissue collected and preserved through this effort for applications such as generation of patient-derived organoids 105 . Thus, the biospecimens collected by the FPC will become an enduring resource for the biomedical and disparities research community.…”

Section: Discussionmentioning

confidence: 99%

The Florida Pancreas Collaborative Next-Generation Biobank: State-wide Infrastructure to Reduce Disparities and Improve Survival for a Racially and Ethnically Diverse Cohort of Patients with Pancreatic Cancer

Permuth¹,

Dezsi²,

Vyas³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Well-annotated, high-quality biorepositories provide a valuable platform to support translational research and discovery. However, most biorepositories have poor representation of minority groups, limiting the ability to address cancer health disparities and improve disease outcomes. This report describes the establishment of the Florida Pancreas Collaborative (FPC), the first state-wide prospective longitudinal cohort study and biorepository specifically designed to address the higher burden of pancreatic cancer (PaCa) in African Americans (AA) compared to Non-Hispanic Whites (NHW) and Hispanic/Latinx (H/L). Methods: We describe rationale for establishing the FPC and provide an overview of key stakeholders; study eligibility and design; ascertainment and recruitment strategies; and standard operating procedures (SOPs) developed to collect, process, store, and transfer biospecimens, medical images, and data. We also describe the customized cloud-based, secure data management platform built to facilitate recruitment, track study-related workflow, house data, and perform queries. We also present progress to date regarding recruitment and biobanking. Results: The FPC consists of multidisciplinary teams from fifteen Florida medical institutions. From March 2019 through August 2020, 350 patients were assessed for study eligibility, 323 met inclusion/exclusion criteria, and 305 (94%) enrolled, including 228 NHW, 30 AA, and 47 H/L, with 94%, 100%, and 94% participation rates, respectively. A high percentage of participants have donated blood (87%), pancreatic tumor tissue (41%), computed tomography scans (76%), and baseline questionnaire data (62%). Conclusions: This biorepository addresses a critical gap in PaCa research with the potential to advance basic, clinical, population-based, and translational studies intended to minimize disparities, increase quality of life, and reduce PaCa-related morbidity and mortality. Impact: This multi-institutional infrastructure can serve as a prototype for development of similar resources across the country and disease sites.

show abstract

“…Most specimens assessed by cancer consortia, including the International Cancer Genome Consortium and The Cancer Genome Atlas, are perioperatively obtained samples of primary tumors, while metastatic tumors usually reflect the lethal phase of cancer. In theory, PTOs enable the expansion of limited tumor specimens, thereby allowing the assessment of malignant cells at all stages [ 61 ]. PTO biobanks broaden the patient sample types that can be studied in the laboratory.…”

Section: Applications Of Ptosmentioning

confidence: 99%

“…The Human Cancer Models Initiative ( https://ocg.cancer.gov/programs/HCMI ) represents a collaborative international consortium building cancer-derived culture models matched to genomic findings and patient features [ 91 ]. The HCMI’s objective is to improve the availability of the built models and relevant information as a community resource [ 53 , 61 ]. Compounded with the technical issues of banking living materials, ethical problems and informed consent challenges associated with such biobanks are complicated.…”

Section: Applications Of Ptosmentioning

confidence: 99%

A pancreas tumor derived organoid study: from drug screen to precision medicine

et al. 2021

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) one of the deadliest malignant tumor. Despite considerable progress in pancreatic cancer treatment in the past 10 years, PDAC mortality has shown no appreciable change, and systemic therapies for PDAC generally lack efficacy. Thus, developing biomarkers for treatment guidance is urgently required. This review focuses on pancreatic tumor organoids (PTOs), which can mimic the characteristics of the original tumor in vitro. As a powerful tool with several applications, PTOs represent a new strategy for targeted therapy in pancreatic cancer and contribute to the advancement of the field of personalized medicine.

show abstract

Establishing a living biobank of patient-derived organoids of intraductal papillary mucinous neoplasms of the pancreas

Cited by 38 publications

References 48 publications

The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pancreatic Cancer

The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pancreatic Cancer

The Florida Pancreas Collaborative Next-Generation Biobank: State-wide Infrastructure to Reduce Disparities and Improve Survival for a Racially and Ethnically Diverse Cohort of Patients with Pancreatic Cancer

A pancreas tumor derived organoid study: from drug screen to precision medicine

Contact Info

Product

Resources

About